Canagliflozin - A One Month Report, Its Good
I've been using Canagliflozin for the past month and really like it. It moderates blood glucose levels and makes it really easy to lose weight. I've lost about 10 lbs in 3 weeks, without really trying.
I researched it after the report form the NIA ITP study came out last year. I tried Acarbose before - but the gas it can cause was less than ideal on occasion. So I've moved over to 100mg of Canagliflozin for the first week, then phased up to 300mg in the morning. It seems to do a really good job of managing post prandial glucose levels - typically 70 to 120 during the day - see my typical daily CGM results in screen capture attached (Note that GCM measures are typically 10 to 20 points lower than I see on my finger prick blood glucose test). I eat a fairly low carb diet anyway - but this helps when I include higher glycemic index foods.
Cost was $2/per 300mg tablet from pharmacy found on Indiamart.com, so a $60/month cost, which I consider reasonable, no prescription required.
Here is the US pharmacy info if you get a prescription:
Its a good complement to Rapamycin. I think I will keep on these for the long term.
Recent Studies, Resources:
Latest Peter Attia Update on Rapamycin and other anti-aging drugs:
"There is another drug that is super exciting called canagliflozin" a more elegant version of acarbose that works in the kidney. Extends life of mice in the ITP study almost as much as rapamycin. "Discussion starts at minute 90 on this new podcast:
Canagliflozin extends life span in genetically heterogeneous male but not female mice
SGLT-2 Inhibitors as Calorie Restriction Mimetics
SGLT2 inhibitors as calorie restriction-mimetics: insights on longevity pathways and age-related diseases
Have you checked your ketone levels through biochemical measures? May I ask what your diet is like- carb intake specifically? Even though Peter Attia is taking it, we still do not have a safety and efficacy study done in healthy populations. I would be interested to see a combination of low-carb combined with sglt2 inhibitor (canagliflozin specifically) for primary endpoints on general health markers. I think canagliflozin has great efficacy for the indication of hyperinsulinemia but I'm worried of a dose-dependant effects on insulin + ketones in a healthy, large population sample.